• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU
Click for more information
0.00% $20.10

NEUREN PHARMACEUTICALS LIMITED

Market Cap $2.569B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
NEU
Ann: Final Director's Interest Notice - T Scott 		09:56 1 858
09:56 Last post  Agent-86 Comments Created with Sketch.  1  Views Created with Sketch.  858 
NEU
Neuren Media and Analyst Coverage
19 20 21
02/07/24 1.2K 619K
02/07/24 Last post  hottod Comments Created with Sketch.  1.2K  Views Created with Sketch.  619K 
NEU
Share Price
178 179 180
02/07/24 10K 4.9M
02/07/24 Last post  ashgood123 Comments Created with Sketch.  10K  Views Created with Sketch.  4.9M 
NEU
Katelin’s Turn is HERE!!!
3 4 5
01/07/24 240 132K
01/07/24 Last post  mellan Comments Created with Sketch.  240  Views Created with Sketch.  132K 
NEU
PHASE2 PRADER WILLI SYNDROME START !!!! 		29/06/24 38 28K
29/06/24 Last post  10%jump Comments Created with Sketch.  38  Views Created with Sketch.  28K 
NEU
What will the drug penetration rates be for NNZ-2591? 		28/06/24 10 3.6K
28/06/24 Last post  seanc Comments Created with Sketch.  10  Views Created with Sketch.  3.6K 
NEU
Ann: Completion of enrolment in Neuren's Angelman P2 trial 		28/06/24 52 35K
28/06/24 Last post  Innameonly Comments Created with Sketch.  52  Views Created with Sketch.  35K 
NEU
Potential Takeover
2 3
28/06/24 131 60K
28/06/24 Last post  hottod Comments Created with Sketch.  131  Views Created with Sketch.  60K 

See All Discussions arrow Created with Sketch.

Timeline

Final Director's Interest Notice - T Scott
02 Jul 16:49
 
Application for quotation of securities - NEU
17 Jun 16:28
 
Change of Director's Interest Notice - J Basile
13 Jun 13:16
 
Corporate Presentation, 29 May 2024
29 May 09:57
 
Results of Meeting
28 May 16:45
 
AGM Chair Address & CEO Presentation
28 May 14:00
 
View More arrow Created with Sketch.

Featured News

ITM iTech lifts MRE at Eyre Peninsula Graphite Project by 300%
right-arrow Created with Sketch.
BIO Biome posts record sales revenue of $13M in FY24 – up 80% vs pcp and higher than forecast
right-arrow Created with Sketch.
LLL Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng
right-arrow Created with Sketch.
AVA Ava Risk Group expands US presence with A$0.7M Substation Deal
right-arrow Created with Sketch.
EX1 Tryptamine Therapeutics completes maiden dosing of IV psilocin – a global first
right-arrow Created with Sketch.
EMD Emyria and UWA secure $499,411 grant to advance MDMA analogue drug program
right-arrow Created with Sketch.

(20min delay)
Last
$20.10 		Change
0.000(0.00%) 		Mkt cap ! $2.569B
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
2 45 $21.00
 

Sellers (Offers)

Price($) Vol. No.
$19.10 1153 2
View Market Depth
Last trade - 09.52am 03/07/2024 (20 minute delay) ?
Last
$20.09 		  Change
0.000 ( 0.05 %)
Open High Low Volume
$20.14 $20.14 $20.04 491
Last updated 10.13am 03/07/2024 ?
NEU (ASX) Chart

Top Stories

Ark Mines inks 1.5Bt Exploration Target for Sandy Mitchell REE play including NdPr; PFS due in Q4

Ark Mines has published an Exploration Target for its Sandy Mitchell REE project of up to 1.5B tonnes @ up to 1490ppm monazite equivalent
Sun Silver to kick off drilling next week at 292Moz Maverick Springs silver-gold project  The company has locked in a drilling contractor to fire up a Reverse Circulation (RC) drill rig at Maverick starting on 8th of July US time. 
Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring Sun Silver executive director Gerard O'Donovan discusses a 6,216 grams Fort Intercept at the Maverick Spring Silver Project from historical data and drill assessments.
Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25 Uranium was one bright spot at the start of 2024, standing out against otherwise glum markets that defined 2023.
ASX Market Open: Bullish Fed comments push ASX200 higher Australian futures are set to rise today on positive US market moves overnight, and bullish comments from the Federal Reserve about rate cuts.

Featured News

BIO Biome posts record sales revenue of $13M in FY24 – up 80% vs pcp and higher than forecast
right-arrow Created with Sketch.
LRV Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%
right-arrow Created with Sketch.
AHK Ark Mines defines significant exploration target at Sandy Mitchell rare earths project
right-arrow Created with Sketch.
EMD Emyria and UWA secure $499,411 grant to advance MDMA analogue drug program
right-arrow Created with Sketch.
ITM iTech lifts MRE at Eyre Peninsula Graphite Project by 300%
right-arrow Created with Sketch.
NEWS Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.